Toujeo (Insulin Glargine) U-300 Approved to Improve Glycemic Control in Adults with Type 1 and Type 2 Diabetes
Diabetes is a chronic disease that affects a staggering 29. million individuals in the United States—approximately 9.3% of the population. In addition, approximately 37% of all US adults aged ≥20 years (51% of individuals aged ≥65 years) have prediabetes, a condition that substantially increases the risk for diabetes. Today, diabetes affects 1 in 10 adults. The prevalence of diabetes is projected to increase to 1 in 3 adults by 2050, based on current trends and the aging of the US population during the next few decades. The appropriate management of diabetes can help to reduce its rising prevalence.
Lemtrada (Alemtuzumab) a New Treatment Option Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis
Multiple sclerosis (MS), a chronic, inflammatory disease of the central nervous system, disrupts the communication between the brain, spinal cord, and other areas of the body. Aside from being potentially debilitating, MS can result in irreversible nerve deterioration. The incidence and prevalence of MS are not consistently tracked in the United States; it is estimated that 400,000 Americans are currently affected by the disease.
Vyvanse (Lisdexamfetamine Dimesylate): First FDA-Approved Drug for the Treatment of Adults with Binge-Eating Disorder
Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma
Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis
Breo Ellipta (Fluticasone Furoate/Vilanterol): Fixed-Dose Oral Inhaler Used for Long-Term Maintenance Treatment of COPD
Chronic obstructive pulmonary disease (COPD) is a common, life-threatening disease characterized by a persistent blockage of airflow from the lungs. COPD encompasses a range of chronic obstructive lung diseases, including chronic bronchitis and emphysema.
Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes
Diabetes, a chronic disease that is often accompanied by multiple comorbidities and health complications, is the seventh leading medical cause of death in the United States. In fact, the mortality rate for patients with diabetes is 1.5 times higher than for individuals without diabetes.
Sivextro (Tedizolid Phosphate) Approved by the FDA for the Treatment of Adults with Acute Bacterial Skin and Skin-Structure Infections
An acute bacterial skin and skin-structure infection (ABSSSI) is a bacterial infection of the skin with a lesion size of e75 cm2, which is measured by the area of redness, edema, or induration. The types of infections that comprise ABSSSIs include cellulitis or erysipelas, major cutaneous abscesses, and wound infections; these infections can be life-threatening and may require hospitalization and surgery.
Page 2 of 2
Results 11 - 18 of 18
Results 11 - 18 of 18